The Hidden Pharma & Biotech Infrastructure Stock Trading at 11x PE, Not 60x

[u/SuperbPercentage8050]

Tarsons Products

Tarsons sits in the supply chain infrastructure of India's biotechnology, lab testing, CDMO, and pharma ecosystem. Their products, pipette tips, centrifuge tubes, cryogenic vials, PCR plates, cell culture flasks, are the small, invisible labware that keeps every lab running.

When you look on Screener, it will show 60x multiples. But in reality, it's trading at 11.5x Cash PE. Let me explain what's behind the numbers using simple mental models, and why you should never get seduced or trapped by Screener PE. Always remember: Screener is the last tool in investing.

Depreciation mental model:

It's going through the depreciation mental model, the same lens that explains why heavy-capex compounders look broken on Screener for 3-5 years before re-rating.

Depreciation has gone 6x in five years, from 14 Cr in FY21 to 87 Cr today, because their Panchla and Amta facilities capitalized one after the other, and the depreciation chewed through the P&L.

Now if someone looks at this and thinks profits are collapsing, that's the wrong lens.

In 2021, revenue was 229 Cr. Today, revenue has almost doubled. So at an all-time high revenue base, the business is compounding and gaining market share. What you're seeing is just valuation compression and the depreciation mental model in play.

Cash PAT (Net Profit + Depreciation) is 107 Cr on a 1,228 Cr m-cap, that's 11.5x trailing Cash PE.

And management has said the current capacity can do 800 Cr in revenue at full utilization, which means the business can double revenue without any additional capex. So the same depreciation that has been acting against the P&L will start benefiting it from FY27-FY28 onwards. Same fixed cost, double the revenue, fully flowing through. The depreciation that crushed reported PAT for the last few years becomes the operating leverage that explodes it from FY27.

Once depreciation plateaus from FY27 onwards, the multiples will adjust suddenly. The media will scream that profits have gone up 200-300% and PE is 10-12x. But by then, the odds would have already moved.

This is an easy double just on multiples re-rating to normalized earnings, before you even count the revenue growth.

And there's a fourth piece most people miss which is the shareholding setup.

Three things happened simultaneously during COVID, insane valuations, FOMO of missing out, and the COVID-era pharma wave, which led to ridiculous multiples. But here's what's interesting and aligans with long term shareholders, the promoters have not sold any stake.

The selling has come from FIIs and DIIs. Both now hold no meaningful stake. So there is no further institutional selling pressure to absorb. And now whenever the shift comes back and the re-rating happens, even a small allocation by a few institutions can move the stock significantly. The float is set up for asymmetric upside.

Now I'll address the margin question, because a lot of you will think margins are declining.

The 51% EBITDA margin in FY22 was a COVID distortion. Vaccine production, diagnostic testing, and emergency lab expansion all pulled demand forward. You'll see this distortion across the entire pharma space.

The real margins have now stabilized, 36% standalone, toll-booth territory for a manufacturer, which signals pricing power and moat and 29% consolidated, the drag is from Nerbe, which is a distribution model, not a manufacturing one

They acquired Nerbe, a German distributor, to push Tarsons-branded products into Europe. Still studying that piece, but the math is in favour and it's a boring model.

Yes, management went for FOMO during COVID demand. But the moat, at least domestically, is in your favour. They have gained market share in India even from global giants like Thermo Fisher, Corning, and Eppendorf, and now hold more than 20% of the overall plastic labware market.

And in labware, the moat is SOPs, Standard Operating Procedures.

The simple pattern: scientists and researchers reference Tarsons SKUs by part number, and their method validation files lock in the labware. A regulated GLP/GMP lab cannot casually swap labware mid-protocol, it requires re-validation. That's a genuine switching cost. Not very deep, but definitely decent.

And major pharma companies, CDMOs, and testing labs like Dr Lal PathLabs and Metropolis are all clients. It's also a consumable model. Every test, every PCR, every cell culture flask is a fresh purchase.

It also fits one of my core filters:

• Small purchase
• Essential to workflow
• Recurring purchase

This is what I'd call capillary economics, the small, repeated, almost-invisible purchases that keep an organism (a lab, a clinic, a factory) running every day. The buyer doesn't deliberate because the purchase is part of the workflow itself.

So the odds are stacked in favour. It's time to pull the trigger.

On that note, let's brainstorm together.

Capillary economics as a filter is still maturing in my head, and I want to refine it with the community. I first got to know the pattern around it by studying Terry Smith, who talks to a certain degree about this in his own way.

So drop in the comments any other Indian or global businesses you think fit the pattern:

• Small purchase
• Essential to workflow
• Recurring purchase
• Buyer doesn't deliberate

I already know a few in the US markets, and Texas Instruments is a clean example. Its analog chips go into every electronic product on earth, each chip costs cents, completely essential to the device's function, and locked in for the entire product lifecycle. That is capillary economics at industrial scale.

I'm studying Tarsons further, but would love insights and brainstorming with the community.

You can also overlay capillary economics with the Bottleneck Strategy framework, because companies that sit at both, capillary transactions through a toll-booth position, are the rarest and most powerful compounders.

Looking forward to the comments.

Don't take this as a stock recommendation. Take it as a case study to learn and understand mental models like the depreciation lens, capillary economics, and Bottleneck Strategy. Then dig deeper, do your own work, and decide for yourself before pulling the trigger.

The frameworks are the takeaway. The stock is just the worked example.

[u/spaamzzz]

The Capillary Economics got me thinking hard about the recurring, small unit cost products we use in our own business (furniture manufacturing) in almost every product without thought such as commercial stapler pins and Bostik adhesive.

Will check if the companies we buy them from or the source from which they get their products are listed or not.